8-K: Kintara Therapeutics Urges Stockholders to Vote in Favor of Merger with TuHURA Biosciences

Kintara Therapeutics is urging its stockholders to vote in favor of the proposed merger with TuHURA Biosciences at the upcoming Special Meeting.

Summary

• Kintara Therapeutics is holding a Special Meeting of Stockholders to vote on a proposed merger with TuHURA Biosciences.
• The merger is an all-stock transaction that aims to combine the expertise and resources of both companies to advance a late-stage oncology pipeline.
• If the merger is approved, pre-merger Kintara equity holders are expected to own approximately 2.85% (or 5.45% including CVR shares) of the combined company, while pre-merger TuHURA equity holders are expected to own approximately 97.15% (or 94.55% including CVR shares).
• The combined company will operate under the name TuHURA Biosciences, Inc. and trade on the Nasdaq Capital Market under the ticker HURA.
• The transaction is expected to close in the third quarter of 2024, subject to customary closing conditions, including stockholder approval from both companies.
• Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to count.
• The Special Meeting will be held virtually on September 20, 2024, at 9:00 a.m., Eastern Time.

Sentiment

Score: 4

Explanation: The document is primarily focused on urging shareholders to vote for the merger, but it also highlights the potential for bankruptcy if the merger fails, and the small ownership stake for Kintara shareholders, which creates a negative sentiment.

Positives

• The merger is expected to create a company with a promising therapeutic pipeline and strong leadership.
• The combined company is expected to have substantial capital resources.
• The merger is expected to position the combined company to develop new therapies that overcome resistance to current immunotherapies.
• The merger is presented as the best path forward for Kintara shareholders, with the potential to deliver both near and long-term value.
• TuHURA has a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy.

Negatives

• Kintara equity holders will own a small percentage of the combined company post-merger.
• If the merger does not close, Kintara may not have sufficient capital to continue operating and may need to seek bankruptcy protection.
• The merger is subject to customary closing conditions, including stockholder approval, which introduces uncertainty.

Risks

• The merger may not be completed if the conditions to closing are not satisfied, including failure to obtain stockholder approval.
• There are uncertainties regarding the timing of the merger and the ability of both companies to complete the transaction.
• There are risks related to estimating operating expenses and merger-related costs, which could impact the combined company's cash resources.
• The merger could be terminated due to unforeseen events or circumstances.
• The announcement of the merger could negatively impact the business relationships and operating results of both companies.
• There are potential legal proceedings related to the merger.
• The combined company may not be successful.
• There is a risk that Kineta and TuHURA do not enter into a definitive agreement for a strategic transaction.

Future Outlook

The combined company is expected to operate under the name TuHURA Biosciences, Inc. and to trade on The Nasdaq Capital Market under the ticker HURA. The transaction is expected to close in the third quarter of 2024.

Management Comments

• The Kintara Board of Directors believes the proposed merger will result in a publicly traded company with a promising therapeutic pipeline, a strong leadership team and substantial capital resources.
• The Board of Directors recommends shareholders support the merger because merging with TuHURA represents the best path forward for our shareholders and has the potential to deliver near and long-term value.
• The Board of Directors is recommending you to vote FOR all proposals presented at the upcoming Special Meeting.

Industry Context

This merger reflects a trend in the biotech industry where companies combine resources to advance drug development pipelines and share risks, particularly in the oncology space. The merger aims to create a stronger entity with a more diversified portfolio.

Comparison to Industry Standards

• The all-stock merger is a common structure in the biotech industry, especially for companies looking to combine resources and expertise.
• The ownership split, with TuHURA shareholders holding the vast majority of the combined company, is typical when a larger, more advanced company merges with a smaller one.
• The focus on immuno-oncology and developing therapies to overcome resistance to checkpoint inhibitors aligns with current industry trends and unmet medical needs.
• TuHURA's lead product candidate, IFx-2.0, is in Phase 3 trials, which is a relatively advanced stage compared to many other biotech companies.
• Kintara's REM-001 therapy has shown 80% complete responses in CMBC, which is a strong efficacy signal compared to other treatments in this area.

Corporate Governance

Stakeholder Impact

• Kintara stockholders will have a significantly reduced ownership stake in the combined company.
• If the merger is successful, the combined company may have a stronger financial position and a more diversified pipeline, potentially benefiting all stakeholders.
• If the merger fails, Kintara may face financial difficulties and potential bankruptcy, negatively impacting all stakeholders.

Next Steps

• Kintara stockholders need to vote on the proposed merger by September 19, 2024.
• The Special Meeting of Stockholders will be held on September 20, 2024.
• The merger is expected to close in the third quarter of 2024, subject to customary closing conditions.

Key Dates

Keywords

merger, Kintara Therapeutics, TuHURA Biosciences, stockholder vote, oncology, biopharmaceutical, Nasdaq, immunotherapy, clinical trials, REM-001, IFx-2.0